Deciphera Pharmaceuticals Inc
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in I… Read more
Market Cap & Net Worth: Deciphera Pharmaceuticals Inc (D05)
Deciphera Pharmaceuticals Inc (F:D05) has a market capitalization of $4.79 Billion (€4.66 Billion) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #4816 globally and #487 in its home market, demonstrating a 6.64% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Deciphera Pharmaceuticals Inc's stock price €53.93 by its total outstanding shares 86476000 (86.48 Million).
Deciphera Pharmaceuticals Inc Market Cap History: 2017 to 2025
Deciphera Pharmaceuticals Inc's market capitalization history from 2017 to 2025. Data shows growth from $1.64 Billion to $4.79 Billion (15.62% CAGR).
Deciphera Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Deciphera Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
8.05x
Deciphera Pharmaceuticals Inc's market cap is 8.05 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $5.06 Billion | $25.00 Million | -$192.26 Million | 202.38x | N/A |
| 2020 | $3.94 Billion | $42.09 Million | -$266.49 Million | 93.64x | N/A |
| 2021 | $727.87 Million | $96.15 Million | -$299.96 Million | 7.57x | N/A |
| 2022 | $1.31 Billion | $134.04 Million | -$178.93 Million | 9.75x | N/A |
| 2023 | $1.31 Billion | $163.36 Million | -$194.94 Million | 8.05x | N/A |
Competitor Companies of D05 by Market Capitalization
Companies near Deciphera Pharmaceuticals Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Deciphera Pharmaceuticals Inc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Deciphera Pharmaceuticals Inc Historical Marketcap From 2017 to 2025
Between 2017 and today, Deciphera Pharmaceuticals Inc's market cap moved from $1.64 Billion to $ 4.79 Billion, with a yearly change of 15.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €4.79 Billion | +23.35% |
| 2024 | €3.88 Billion | +195.21% |
| 2023 | €1.31 Billion | +0.58% |
| 2022 | €1.31 Billion | +79.57% |
| 2021 | €727.87 Million | -81.53% |
| 2020 | €3.94 Billion | -22.11% |
| 2019 | €5.06 Billion | +214.05% |
| 2018 | €1.61 Billion | -2.00% |
| 2017 | €1.64 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Deciphera Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.79 Billion USD |
| MoneyControl | $4.79 Billion USD |
| MarketWatch | $4.79 Billion USD |
| marketcap.company | $4.79 Billion USD |
| Reuters | $4.79 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.